Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Jared M. Fine"'
Autor:
Jared M. Fine, Jacob Kosyakovsky, Amanda M. Baillargeon, Julian V. Tokarev, Jacob M. Cooner, Aleta L. Svitak, Katherine A. Faltesek, William H. Frey II, Leah R. Hanson
Publikováno v:
Brain and Behavior, Vol 10, Iss 3, Pp n/a-n/a (2020)
Abstract Introduction Intranasal deferoxamine (IN DFO) has been shown to decrease memory loss and have beneficial impacts across several models of neurologic disease and injury, including rodent models of Alzheimer's and Parkinson's disease. Methods
Externí odkaz:
https://doaj.org/article/ddb5a9d4b46347c0abe5269c4f0e207b
Publikováno v:
Pharmaceuticals, Vol 14, Iss 2, p 95 (2021)
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present the rationale for intranasal (IN) delivery of deferoxamine (DFO), a high-affinity iron chelator, as a treatment
Externí odkaz:
https://doaj.org/article/a26d39a7966e4d1ca7cac70db418906b
Autor:
Gunda I. Georg, Usha Mishra, Davin Rautiola, Ronald A. Siegel, Narsihmulu Cheryala, Katherine A. Faltesek, Kathryn M. Nelson, Aleta L. Svitak, Lisa D. Coles, James C. Cloyd, Jared M. Fine, Leah R. Hanson, Patricia D. Maglalang
Publikováno v:
J Pharmacol Exp Ther
Intranasal administration is an attractive route for systemic delivery of small, lipophilic drugs because they are rapidly absorbed through the nasal mucosa into systemic circulation. However, the low solubility of lipophilic drugs often precludes aq
Autor:
Katherine A. Faltesek, Jacob Kosyakovsky, Jared M. Fine, Aleta L. Svitak, Leah R. Hanson, Jacob M. Cooner, Amanda M. Baillargeon, William H. Frey, Julian Tokarev
Publikováno v:
Brain and Behavior
Brain and Behavior, Vol 10, Iss 3, Pp n/a-n/a (2020)
Brain and Behavior, Vol 10, Iss 3, Pp n/a-n/a (2020)
Introduction Intranasal deferoxamine (IN DFO) has been shown to decrease memory loss and have beneficial impacts across several models of neurologic disease and injury, including rodent models of Alzheimer's and Parkinson's disease. Methods In order
Autor:
Davin Rautiola, Leah R. Hanson, James C. Cloyd, Patricia D. Maglalang, Lisa D. Coles, Jared M. Fine, Ronald A. Siegel
Publikováno v:
Epilepsia. 59:207-215
A subgroup of patients with drug-resistant epilepsy have seizure clusters, which are a part of the continuum of seizure emergencies that includes prolonged episodes and status epilepticus. When the patient or caregiver can identify the beginning of a
Autor:
Anna C. Forsberg, Jean M. Crow, E.B. Raney, Jared M. Fine, Leah R. Hanson, Katherine A. Faltesek, K.E. Knutzen, Benjamin M. Stroebel, William H. Frey, K.D. Kaczmarczek, L.R. Haase, Katherine A. Hamel, D.R. Verden
Publikováno v:
Journal of the Neurological Sciences. 380:164-171
Accumulation of metal and the accompanying increase in oxidative stress and inflammation plays an important role in neurodegenerative disease. Deferoxamine (DFO) is a metal chelator found to be beneficial in several animal models of neurodegenerative
Autor:
Aleta L. Svitak, Leah R. Hanson, Bruce A. Witthuhn, Jared M. Fine, William H. Frey, Jacob Kosyakovsky
Publikováno v:
ACS chemical neuroscience. 10(11)
Deferoxamine, a metal chelator, has been shown to be neuroprotective in animal models of ischemic stroke, traumatic brain injury and both subarachnoid and intracerebral hemorrhage. Intranasal deferoxamine (IN DFO) has also shown promise as a potentia
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 95, p 95 (2021)
Pharmaceuticals, Vol 14, Iss 95, p 95 (2021)
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present the rationale for intranasal (IN) delivery of deferoxamine (DFO), a high-affinity iron chelator, as a treatment
Autor:
Jared M. Fine, Deborah Bingham, Leah R. Hanson, William H. Frey, Aleta L. Svitak, Shyeilla V. Dhuria, S. Scott Panter, Amanda M. Baillargeon, Rachel B. Burns, Abdul N. Kazi
Publikováno v:
Neuroscience Letters. 627:155-159
Hypocretin-1 (HC, orexin-A) is a neuropeptide involved in regulating physiological functions of sleep, appetite and arousal, and it has been shown that intranasal (IN) administration can target HC to the brain. Recent clinical studies have shown that
Autor:
Kristin E. Knutzen, Kaoru Terai, Austin K. Fuller, Jacob Kosyakovsky, Lucas Haase, Katherine A. Faltesek, William H. Frey, Leah R. Hanson, Jared M. Fine, Benjamin M. Stroebel, Tate J. Bowe
Publikováno v:
Neuroscience Letters. 714:134567
Emerging evidence continues to demonstrate that disrupted insulin signaling and altered energy metabolism may play a key role underpinning pathology in neurodegenerative conditions. Intranasally administered insulin has already shown promise as a mem